Isofol Medical AB (publ) announced that its Board of Directors has appointed Anders Edvell as a co-opted member of the Board. This is following the resignation of Jan-Eric Österlund, who has decided to resign as Board Director and instead will take a new role as senior advisor to the company. The board has decided to co-opt Anders Edvell to the board of Isofol.

Anders Edvell has over 20 years of experience in the pharmaceutical industry and is currently CEO of Immedica Pharma, a pharmaceutical company focused on commercialization of medicines for rare diseases and special diseases. He has previously been CEO at Unimedic Pharma, VP Global Product Strategies and Head of Partner Products at Sobi, Country Manager at Swedish Orphan, and held several leading medical roles at Bristol-Myers Squibb and Recip.